H Hamana Selected Research

carboxymethylpullulan- phenylglycyl- doxorubicin conjugate

12/2000

Improved in vivo antitumor efficacy and reduced systemic toxicity of carboxymethylpullulan-peptide-doxorubicin conjugates.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

H Hamana Research Topics

Disease

3	Neoplasms (Cancer) 05/2001 - 05/2000
2	Carcinosarcoma 05/2001 - 05/2000
2	Body Weight (Weight, Body) 02/2001 - 12/2000
1	Autoimmune Diseases (Autoimmune Disease) 02/2001
1	Experimental Arthritis 02/2001
1	Neoplasm Metastasis (Metastasis) 12/2000
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2000
1	Edema (Dropsy) 01/2000

Drug/Important Bio-Agent (IBA)

4	carboxymethylpullulanIBA 02/2001 - 01/2000
3	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2001 - 05/2000
2	Peptides (Polypeptides)IBA 05/2001 - 05/2000
1	9-carboxymethoxymethylguanineIBA 05/2001
1	Polysaccharides (Glycans)IBA 05/2001
1	Drug CarriersIBA 05/2001
1	pironetinIBA 02/2001
1	Immunosuppressive Agents (Immunosuppressants)IBA 02/2001
1	Antineoplastic Agents (Antineoplastics)IBA 12/2000
1	carboxymethylpullulan- phenylglycyl- doxorubicin conjugateIBA 12/2000
1	phenylalanylglycineIBA 12/2000
1	pullulanIBA 05/2000
1	LigandsIBA 01/2000
1	Sialyl Lewis X AntigenIBA 01/2000
1	E-SelectinIBA 01/2000

Therapy/Procedure

2	Intravenous Injections 05/2001 - 05/2000
1	Drug Therapy (Chemotherapy) 05/2000
1	Intravenous Administration 01/2000